Patents Examined by Robert M. Kelly
  • Compositions and methods for immune cell modulation in adoptive immunotherapies
    Patent number: 11096964
    Abstract: Compounds that either produced a higher proportion or greater absolute number of phenotypically identified nave, stem cell memory, central memory T cells, adaptive NK cells, and type I NKT cells are identified. Compositions and methods for modulating immune cells including T, NK, and NKT cells for adoptive cell therapies with improved efficacy are provided.
    Type: Grant
    Filed: January 20, 2017
    Date of Patent: August 24, 2021
    Assignee: FATE THERAPEUTICS, INC.
    Inventors: Jonathan Rosen, Betsy Rezner, Bahram Valamehr, Ryan Bjordahl, Eigen Peralta
  • Method for efficient delivery of therapeutic molecules in vitro and in vivo
    Patent number: 11071790
    Abstract: Compositions are described for direct protein delivery into multiple cell types in the mammalian inner ear. The compositions are used to deliver protein(s) (such as gene editing factors) editing of genetic mutations associated with deafness or associated disorders thereof. The delivery of genome editing proteins for gene editing and correction of genetic mutations protect or restore hearing from genetic deafness. Methods of treatment include the intracellular delivery of these molecules to a specific therapeutic target.
    Type: Grant
    Filed: October 29, 2015
    Date of Patent: July 27, 2021
    Assignees: Massachusetts Eye and Ear Infirmary, President and Fellows of Harvard College
    Inventors: Zheng-Yi Chen, David R. Liu, Margie Li, David B. Thompson, John Zuris
  • Materials and methods for treatment of usher syndrome type 2A
    Patent number: 11072792
    Abstract: The present application provides materials and methods for treating a patient with Usher Syndrome Type 2A, both ex vivo and in vivo; materials and methods for editing a USH2A gene in a human cell; materials and methods for editing an USH2A gene containing an IVS40 mutation; materials and methods for treating a patient with an USH2A gene containing an IVS40 mutation; and a method for deleting a sequence comprising an IVS40 mutation within a USH2A gene of a cell. The present application also provides one or more gRNAs or sgRNAs for editing an USH2A gene containing an IVS40 mutation. The present application provides a therapeutic for treating a patient with Usher Syndrome Type 2A. The present application also provides a kit for treating a patient with Usher Syndrome Type 2A.
    Type: Grant
    Filed: June 18, 2020
    Date of Patent: July 27, 2021
    Assignees: BAYER HEALTHCARE LLC, CRISPR THERAPEUTICS AG
    Inventors: Albena Kantardzhieva, Akiko Noma, Abraham Scaria
  • RNA for use in the treatment of ligament or tendon lesions
    Patent number: 11065346
    Abstract: Described is a liquid composition containing naked RNA, such as mRNA encoding a polypeptide, for use in the treatment or prevention of ligament or tendon lesions as well as a method for treating ligament or tendon lesions comprising the administration of a liquid composition containing naked RNA, such as mRNA encoding a polypeptide, which is beneficial in the process of healing the ligament or tendon lesions.
    Type: Grant
    Filed: April 29, 2019
    Date of Patent: July 20, 2021
    Assignee: ethris GmbH
    Inventors: Günther Hasenpusch, Carsten Rudolph
  • Liposomal compositions and uses of same
    Patent number: 11065203
    Abstract: Compositions comprising liposomes composed of whole cell membrane fraction are provided. The liposomes may be attached to, or encapsulate a pharmaceutical agent. Also provided are methods of generating and using these liposomes.
    Type: Grant
    Filed: April 2, 2019
    Date of Patent: July 20, 2021
    Assignee: Techmon Research & Development Foundation Limited
    Inventors: Marcelle Machluf, Tomer Bronshtein
  • Compositions and methods for tumor transduction
    Patent number: 11059904
    Abstract: The invention relates to cancer therapeutics, in particular, the system of making cancer cells more susceptible to effector cells by introduction of cellular therapy targets into the cancer cells.
    Type: Grant
    Filed: August 1, 2018
    Date of Patent: July 13, 2021
    Assignee: Aleta Biotherapeutics Inc.
    Inventors: Roy Lobb, Paul Rennert
  • Restimulation of cryopreserved tumor infiltrating lymphocytes
    Patent number: 11058728
    Abstract: The present disclosure provides methods for re-stimulating TIL populations that lead to improved phenotype and increased metabolic health of the TILs and provides methods of assaying for TIL populations to determine suitability for more efficacious infusion after re-stimulation.
    Type: Grant
    Filed: April 8, 2021
    Date of Patent: July 13, 2021
    Assignee: Iovance Biotherapeutics, Inc.
    Inventors: Ian Frank, Michael T. Lotze
  • Use of car and bite technology coupled with an SCFV from an antibody against human thymidine kinase 1 to specifically target tumors
    Patent number: 11052138
    Abstract: A nucleic acid encoding a chimeric antigen receptor (CAR) comprising a single-chain variable fragment (scFv) operatively linked to a signaling domain that polarizes a macrophage to an M1 macrophage; wherein the nucleic acid is operatively linked to a macrophage specific promoter; and wherein the scFv is specific for a human antigen. Monocytes or macrophages comprising such a nucleic acid.
    Type: Grant
    Filed: September 5, 2018
    Date of Patent: July 6, 2021
    Assignee: Thunder Biotech Inc.
    Inventors: Kim Leslie O'Neill, Scott Weber
  • Intracellular delivery method
    Patent number: 11052394
    Abstract: A method and device for transfecting a cell to introduce an exogenous material into the cell. The method includes exposing the cell to a region of unsteady flow in the presence of an electric field to encourage introduction of the exogenous material into a cell without lysing the cell.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: July 6, 2021
    Assignee: INDEE. PTY. LTD.
    Inventors: Ryan Pawell, Amy Twite, Geoff Facer, Katherine Lau, Adrian Lievano, Julyana Acevedo
  • Lipid nanoparticle compositions and methods for mRNA delivery
    Patent number: 11052159
    Abstract: Disclosed herein are compositions and methods for modulating the production of a protein in a target cell. The compositions and methods disclosed herein are capable of ameliorating diseases associated with protein or enzyme deficiencies.
    Type: Grant
    Filed: November 16, 2020
    Date of Patent: July 6, 2021
    Assignee: TRANSLATE BIO, INC.
    Inventors: Braydon Charles Guild, Frank DeRosa, Michael Heartlein
  • Method of producing renal cells from differentiated cells
    Patent number: 11046932
    Abstract: The present invention relates to a method for producing renal cells, comprising overexpressing Hnf1b and Pax8, and optionally Hnf4a and/or Emx2 in differentiated cells.
    Type: Grant
    Filed: January 25, 2017
    Date of Patent: June 29, 2021
    Assignee: Albert-Ludwigs-Universitaet Freiburg
    Inventors: Soeren Lienkamp, Michael Kaminski, Sebastian Arnold, Gerd Walz
  • Compositions for use in recovering or ameliorating deterioration of physiological functions due to aging
    Patent number: 11041006
    Abstract: The present invention provides compositions for use in recovering and/or ameliorating deterioration of physiological functions due to aging. Provided are: a cell overexpressing GDF6 protein or an miR-17 family member; a composition for use in treating a senescence-related condition, containing GDF6 protein; a composition for use in treating a senescence-related condition, containing a human expression vector for GDF6 protein or an miR-17 family member; and a composition for use in treating a senescence-related condition, containing a cell secreting GDF6 protein.
    Type: Grant
    Filed: December 27, 2016
    Date of Patent: June 22, 2021
    Assignee: RIKEN
    Inventor: Hayato Kaneda
  • Deterministic stepping of polymers through a nanopore
    Patent number: 11035847
    Abstract: In a method p for controlling translocation of a target polymer molecule through a nanopore, a clamp is reversibly bound to a sequential plurality of polymer subunits along the target polymer molecule length and the molecule and clamp are disposed in an ionic solution that is in fluidic communication with the nanopore. A constant translocation force is applied across the nanopore to induce travel of the target polymer molecule into the nanopore, until the clamp abuts the nanopore aperture and stops further travel of the target polymer molecule into the nanopore. Then a voltage control pulse is applied across the nanopore and/or a thermal control pulse is applied at the nanopore, with a pulse duration that steps the clamp along the target polymer molecule by no more than one polymer subunit in a direction opposite that of travel into the nanopore. No fuel is provided to the clamp.
    Type: Grant
    Filed: June 28, 2018
    Date of Patent: June 15, 2021
    Assignee: President and Fellows of Harvard College
    Inventors: Daniel Branton, Stephen Jordan Fleming, Jene A. Golovchenko
  • Immunoadsorption
    Patent number: 11033639
    Abstract: Upon administration of rAAV vectors the humoral immune response (neutralizing antibodies) is the first barrier that needs to be overcome. Surprisingly it was found that by using immunoadsorption for depletion of immunoglobulins from the blood (plasma), subjects can be highly efficiently treated with rAAV vectors, i.e. obtain highly efficient transduction after rAAV vector administration, in spite of the presence of high levels of nAb.
    Type: Grant
    Filed: April 15, 2019
    Date of Patent: June 15, 2021
    Assignee: UNIQURE IP B.V.
    Inventor: Valerie Ferreira
  • Methods for selectively expanding and enriching cells transduced with chimeric antigen receptors and treating HIV infection
    Patent number: 11034933
    Abstract: Disclosed herein are methods for selectively expanding cells expressing chimeric antigen receptors and enriching cells expressing chimeric antigen receptors in compositions and methods of treating HIV infection in subjects by administering the expanded and/or enriched cells.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: June 15, 2021
    Assignee: The Regents of the University of California
    Inventors: Otto O. Yang, Ayub Ali, Hwee Ng, Scott G. Kitchen, Jerome A. Zack, Irvin Chen
  • Restimulation of cryopreserved tumor infiltrating lymphocytes
    Patent number: 11026974
    Abstract: The present disclosure provides methods for re-stimulating TIL populations that lead to improved phenotype and increased metabolic health of the TILs and provides methods of assaying for TIL populations to determine suitability for more efficacious infusion after re-stimulation.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: June 8, 2021
    Assignee: Iovance Biotherapeutics, Inc.
    Inventors: Ian Frank, Michael T. Lotze
  • Recombinant influenza viruses and constructs and uses thereof
    Patent number: 11028408
    Abstract: Disclosed are compositions and methods comprising one or more recombinant influenza viruses. Recombinant influenza viruses with mutated polymerases and/or rearranged genomes are disclosed. Constructs comprising different influenza nucleic acid sequences are also provided. Methods of inducing protecting immunity with the recombinant influenza viruses are disclosed. Also disclosed are methods of plasmid-free production of influenza virus comprising amplicons comprising one or more of influenza genes.
    Type: Grant
    Filed: May 28, 2013
    Date of Patent: June 8, 2021
    Assignee: UNIVERSITY OF MARYLAND, COLLEGE PARK
    Inventors: Daniel R. Perez, Hongjun Chen, Yibin Cai, Lindomar Jose Pena, Matthew Angel
  • Oil-in-water emulsions that contain nucleic acids
    Patent number: 11026890
    Abstract: This invention generally relates to cationic oil-in-water emulsions that can be used to deliver nucleic acid molecules, such as an RNA molecule. The emulsion particles comprise an oil core and a cationic lipid. The emulsion particles have an average diameter of about 80 nm to about 180 nm, and the emulsion have an N/P ratio of at least 1.1:1.
    Type: Grant
    Filed: May 2, 2019
    Date of Patent: June 8, 2021
    Assignee: GlaxoSmithKline Biologicals SA
    Inventors: Luis Brito, Michelle C. Archer, Andrew Geall, Derek O'Hagan, Manmohan Singh
  • Functionalized erythroid cells
    Patent number: 11020435
    Abstract: Described herein are novel preparations of functionalized erythroid cells and related compositions, reagents, and methods for use in human pharmaceutical and veterinary applications.
    Type: Grant
    Filed: February 16, 2018
    Date of Patent: June 1, 2021
    Assignee: Rubius Therapeutics, Inc.
    Inventors: Tom Wickham, Tiffany F. Chen, Xuqing Zhang, Carolyn Sayre, Jordi Mata-Fink, Sivan Elloul, Billy Law, Lenka Hoffman, Kristian Eric Teichert, Shamael Rabia Dastagir
  • Compositions for introducing nucelic acid into cells
    Patent number: 11020487
    Abstract: The present invention relates to polymers comprising a characteristic combination of alkylene amine moieties which are useful as vehicles for transfecting a cell with a nucleic acid. The present invention furthermore relates to a composition comprising a nucleic acid and such a polymer, and to a method of transfecting a cell using said composition. Furthermore, the present invention relates to pharmaceutical compositions and uses.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: June 1, 2021
    Assignee: ethris GmbH
    Inventors: Christian Dohmen, Christian Plank, Carsten Rudolph